GRN and neuroblastoma: We confirmed that similar treatment with a miR-29b inhibitor increases progranulin protein levels in differentiated SH-SY5Y human neuroblastoma cells (Fig. S1) and in H4 human neuroglioma cells (Fig. 1A), which have moderate expression of miR-29b (Fig. S2A).